<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255734</url>
  </required_header>
  <id_info>
    <org_study_id>YSP-REH3002-01</org_study_id>
    <nct_id>NCT02255734</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Two Formulations of Acyclovir</brief_title>
  <official_title>Bioequivalence of Two Formulations of Acyclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yung Shin Pharm. Ind. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yung Shin Pharm. Ind. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence of two formulations of Acyclovir (Acyclovir Lyophilized I.V. infusion 250mg)
      after Intravenous Infusion in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration</measure>
    <time_frame>Day 1, Day 2</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Zovirax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Virless</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyclovir</intervention_name>
    <arm_group_label>Zovirax</arm_group_label>
    <arm_group_label>Virless</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male or female subjects between 20 to 45 years of age

          -  Body weight within 80 to 120 percentages of ideal body weight and higher than or equal
             to 50 kg for male subjects and 45 kg for female subjects

          -  Acceptable medical history and physical examination including no particular clinically
             significant abnormality in x-ray and ECG results within six months prior to period I
             dosing.no particular clinical significance in general disease history within two
             months prior to period I dosing

          -  Acceptable vital signs within normal limits or considered by the investigator or
             physician to be of no clinical significance at screening, which includes pulse rate,
             blood pressure and body temperature

          -  Acceptable clinical chemistry determinations within normal limits or considered by the
             investigator or physician to be of no clinical significance within two months prior to
             Period I dosing, which includes AST , ALT ,GT, alkaline phosphatase, total bilirubin,
             albumin, glucose, BUN, uric acid, creatinine, total cholesterol and triglyceride

          -  Acceptable hematology within normal range or considered by the investigator or
             physician to be of no clinical significance within two months prior to Period I
             dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell
             count with differentials and platelets

          -  Acceptable urinalysis within normal limits or considered by the investigator or
             physician to be of no clinical significance within two months prior to Period I
             dosing, which includes pH, blood, glucose, ketones, bilirubin and protein

          -  Female subjects of childbearing potential practicing an acceptable method of birth
             control for the duration of the study as judged by the investigators or surgically
             sterile bilateral tubal ligation, bilateral oophorectomy or hysterectomy performed on
             the subject

          -  Have signed the written informed consent to participate in the study

        Exclusion Criteria:

          -  A clinically significant disorder involving the cardiovascular, respiratory, hepatic,
             renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic systems or
             psychiatric disease as determined by the clinical investigator

          -  A clinically significant illness or surgery within four weeks prior to Period I dosing
             as determined by the investigator

          -  History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder
             disease, pancreas disorder over last two years or history of gastrointestinal tract
             surgery over last five years

          -  History of kidney disease or urination problem over last two years deemed by the
             investigator to be clinically significant

          -  Known or suspected history of drug abuse within lifetime as judged by the investigator

          -  History of alcohol addiction or abuse within last five years as judged by the
             investigator

          -  History of allergic responses to acyclovir, valacyclovir or any other related drugs

          -  Evidence of chronic or acute infectious diseases

          -  Female subjects demonstrating a positive urine pregnancy screen prior to the study

          -  Female subjects who are currently breastfeeding

          -  Taking any drug known to induce or inhibit hepatic drug metabolism within four weeks
             prior to Period I dosing. Examples of inducers include. piperidines, carbamazepine,
             dexamethasone and rifampin. Examples of inhibitors include: cimetidine,
             diphenhydramine, fluvastatin, methadone and ranitidine

          -  Taking any prescription medications within four weeks or any nonprescription
             medications excluding flu vaccination within two weeks prior to Period I dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Yen Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

